Fresh analysis indicates that patients who come off new GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass far faster than those who end traditional lifestyle regimens.
Research printed in a prominent health publication demonstrates that while obese people frequently drop about a fifth of their total mass while on the medication, the weight comes back at an average rate of nearly a kilo each month upon discontinuation.
"Individuals using such drugs must be cognizant of the risk of fast weight regain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery suggests a reversion to starting mass in about 18 months.
Comparing Therapies
The research, which looked at 37 of trials involving over 9,000 of participants, compared the results of these new drugs with conventional dieting.
The team note that individuals who shed pounds through diet and exercise generally experience a slower creep back—perhaps 100 grams monthly—after stopping.
Understanding the Quick Regain
Doctors believe the way of the jabs is key to understanding the heightened regain.
The injections imitate a natural hormone called glucagon-like peptide-1, which controls hunger.
"Long-term administration of the hormone concentrations far above than normal may cause the body to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' means appetite is no longer kept in check, making binge eating far more likely."
A Chronic Issue?
Medical guidelines recommend the injections for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Professionals say that, considering the likelihood of weight regain, the therapy should be considered ongoing.
This view is supported by drug manufacturers, who note that the findings "underscore the persistent nature of excess weight," akin to managing conditions like hypertension.
Patient Testimonies
People who have stopped the jabs describe a sudden resurgence of cravings.
"It felt as if something that goes on and I was suddenly extremely hungry," recalled a patient.
This difficulty is worsened if individuals have not established sustainable lifestyle or habit modifications during treatment.
Growing Interest
Survey data show that millions of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is higher among females than men.
- The 40s and 50s age group shows the highest level of interest.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, experts emphasize that while the jabs are potent tools for weight loss, they are not a standalone cure and lasting health benefits relies on ongoing behavioural support.
